Form 4: Axogen CEO Vests 150,000 Performance Shares
Insider Transaction Report
Axogen, Inc. CEO Michael D. Dale acquired 150,000 shares of common stock through the vesting of performance-based awards.
Summary
- Michael D. Dale, Chief Executive Officer of Axogen, Inc. (AXGN), acquired 150,000 shares of the company's common stock.
- The transaction occurred on December 4, 2025, with the shares acquired at a price of $0, indicating a vesting event rather than a purchase.
- The shares vested upon the attainment of certain performance criteria.
- Following this transaction, Mr. Dale directly beneficially owns 150,000 shares of Axogen, Inc. common stock.
- The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 7
Explanation: The vesting of performance-based shares for the CEO is generally positive, as it indicates that the company met specific performance criteria. This aligns management's interests with shareholders and reflects positively on past performance.
Positives
- The vesting of 150,000 shares for CEO Michael D. Dale indicates that specific performance criteria set by Axogen, Inc. were successfully met.
- The transaction increases the CEO's direct beneficial ownership to 150,000 shares, potentially aligning management and shareholder interests.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.
Industry Context
This insider transaction reflects a standard practice of executive compensation where equity awards, such as performance shares, vest upon the achievement of pre-defined corporate goals. Such vesting events are common across publicly traded companies as a means to incentivize and retain key management personnel.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was executed under a Rule 10b5-1(c) plan, which allows insiders to establish a predetermined plan for buying or selling company stock to avoid accusations of insider trading. | 12/04/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reporting person. |
Stakeholder Impact
- Shareholders: The increase in the CEO's direct beneficial ownership to 150,000 shares may be viewed positively, as it further aligns management's financial interests with those of the shareholders.
- Employees: The vesting of performance shares for the CEO could signal successful company performance, potentially boosting morale.
Key Dates
| Date | Description |
|---|---|
| 12/04/2025 | Date of earliest transaction, when 150,000 shares vested upon attainment of performance criteria. |
| 12/05/2025 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed and filed. |
Keywords
Axogen, AXGN, Michael D. Dale, CEO, Form 4, Insider Transaction, Stock Vesting, Performance Shares, Equity Compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.